The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Sends Warning Letters to More Than 50 GLP 1 Compounders and Manufacturers Wilson Sonsini RFK Jr.'s peptide push could unleash risky drugs STAT First Opinion Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law September 8, 2025: FDA launches an import alert listing safe GLP 1 manufacturers Partnership for Safe Medicines FDA's Legislative Request on Rx and Compounded Drug Advertising Coalition for Healthcare Communication